Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
06
01
2023
accepted:
10
08
2023
revised:
13
07
2023
pmc-release:
21
08
2024
medline:
23
10
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
We aimed to study adherence to cardiac screening in long-term childhood cancer survivors (CCS) at high risk of cardiomyopathy. This study involved 976 5-year CCS at high risk for cardiomyopathy from the French Childhood Cancer Survivor Study. Determinants of adherence to recommended surveillance were studied using multivariable logistic regression models. Association of attendance to a long-term follow-up (LTFU) visit with completion of an echocardiogram was estimated using a Cox regression model. Among participants, 32% had an echocardiogram within the 5 previous years. Males (adjusted RR [aRR] 0.71, 95% CI 0.58-0.86), survivors aged 36-49 (aRR 0.79, 95% CI 0.64-0.98), Neuroblastoma (aRR 0.53, 95% CI 0.30-0.91) and CNS tumour survivors (aRR 0.43, 95% CI 0.21-0.89) were less likely to adhere to recommended surveillance. Attendance to an LTFU visit was associated with completion of an echocardiogram in patients who were not previously adherent to recommendations (HR 8.20, 95% CI 5.64-11.93). The majority of long-term survivors at high risk of cardiomyopathy did not adhere to the recommended surveillance. Attendance to an LTFU visit greatly enhanced the completion of echocardiograms, but further interventions need to be developed to reach more survivors.
Sections du résumé
BACKGROUND
We aimed to study adherence to cardiac screening in long-term childhood cancer survivors (CCS) at high risk of cardiomyopathy.
METHODS
This study involved 976 5-year CCS at high risk for cardiomyopathy from the French Childhood Cancer Survivor Study. Determinants of adherence to recommended surveillance were studied using multivariable logistic regression models. Association of attendance to a long-term follow-up (LTFU) visit with completion of an echocardiogram was estimated using a Cox regression model.
RESULTS
Among participants, 32% had an echocardiogram within the 5 previous years. Males (adjusted RR [aRR] 0.71, 95% CI 0.58-0.86), survivors aged 36-49 (aRR 0.79, 95% CI 0.64-0.98), Neuroblastoma (aRR 0.53, 95% CI 0.30-0.91) and CNS tumour survivors (aRR 0.43, 95% CI 0.21-0.89) were less likely to adhere to recommended surveillance. Attendance to an LTFU visit was associated with completion of an echocardiogram in patients who were not previously adherent to recommendations (HR 8.20, 95% CI 5.64-11.93).
CONCLUSIONS
The majority of long-term survivors at high risk of cardiomyopathy did not adhere to the recommended surveillance. Attendance to an LTFU visit greatly enhanced the completion of echocardiograms, but further interventions need to be developed to reach more survivors.
Identifiants
pubmed: 37604931
doi: 10.1038/s41416-023-02400-0
pii: 10.1038/s41416-023-02400-0
pmc: PMC10575933
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1298-1305Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Support Care Cancer. 2018 Jul;26(7):2361-2368
pubmed: 29417294
Cancer. 2023 Nov 1;129(21):3476-3489
pubmed: 37432135
BMC Public Health. 2009 Jan 22;9:33
pubmed: 19161613
Arch Intern Med. 2009 Mar 9;169(5):454-62
pubmed: 19273775
Circulation. 2013 Oct 22;128(17):1927-95
pubmed: 24081971
J Cancer Surviv. 2013 Sep;7(3):275-82
pubmed: 23471729
J Natl Cancer Inst. 2009 Aug 19;101(16):1131-40
pubmed: 19648511
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Oncologist. 2008 Nov;13(11):1181-92
pubmed: 18987046
J Cancer Surviv. 2019 Oct;13(5):713-729
pubmed: 31338733
J Clin Oncol. 2014 Dec 10;32(35):3974-81
pubmed: 25366684
CMAJ. 2012 May 15;184(8):895-9
pubmed: 22158397
J Cancer Surviv. 2008 Dec;2(4):225-32
pubmed: 18787958
Neuro Oncol. 2015 May;17(5):747-56
pubmed: 25422316
JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
Lancet Oncol. 2015 Mar;16(3):e123-36
pubmed: 25752563
J Cancer Surviv. 2017 Oct;11(5):614-623
pubmed: 28785871
JAMA. 2009 Jan 28;301(4):404-14
pubmed: 19176442
J Clin Oncol. 2020 Jun 1;38(16):1785-1796
pubmed: 32196392
J Natl Cancer Inst. 2018 Dec 1;110(12):1352-1359
pubmed: 29771337
J Cancer Surviv. 2016 Aug;10(4):711-25
pubmed: 26833205
Soc Sci Med. 2000 May;50(10):1385-401
pubmed: 10741575
J Clin Oncol. 2008 Sep 20;26(27):4401-9
pubmed: 18802152
Eur J Heart Fail. 2019 Apr;21(4):509-518
pubmed: 30592114
Pediatr Clin North Am. 2020 Dec;67(6):1135-1154
pubmed: 33131538
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
Ann Oncol. 2012 Aug;23(8):2191-2198
pubmed: 22312159
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
J Cancer Surviv. 2013 Sep;7(3):379-91
pubmed: 23568405
Circulation. 2004 Jun 29;109(25):3122-31
pubmed: 15226229
Cancer Treat Rev. 2010 Jun;36(4):277-85
pubmed: 20231056
Eur J Cancer. 2012 May;48(7):1066-73
pubmed: 21737254
J Cancer Surviv. 2015 Dec;9(4):692-8
pubmed: 25764272
Pediatr Blood Cancer. 2011 May;56(5):818-24
pubmed: 21370417
J Clin Oncol. 2010 Mar 10;28(8):1308-15
pubmed: 20142603
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Cancer. 2004 Feb 15;100(4):843-50
pubmed: 14770443
BMJ. 2013 Mar 27;346:f1190
pubmed: 23535255